Every 8-K that Biote Corp. (BTMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTMD filings page.
Biote Corp. reported second quarter 2026 revenue of $44.2 million, down 9.5% from $48.9 million a year earlier. Procedure revenue declined 13.9% to $30.3 million, reflecting impacts from the January 2026 voluntary recall of certain hormone pellets shipped by Asteria Health, while dietary supplements revenue grew 5.7% to $11.4 million.
Gross profit margin fell to 65.4% from 71.6%, driving an operating loss of $3.5 million versus $10.8 million of income, and a net loss of $7.4 million, or $(0.23) per diluted share, compared with $3.9 million and $0.10. Adjusted EBITDA was $5.6 million with a 12.6% margin, down from $15.2 million and 31.1%. Recall-related costs totaled $0.8 million in the quarter and $2.2 million year-to-date. As of June 30, 2026, cash was $11.2 million, total liabilities were $159.9 million, and stockholders’ deficit was $58.2 million. For 2026, Biote now guides to revenue above $175 million and Adjusted EBITDA above $25 million, expecting sequential improvement but continued year-over-year declines in procedure revenue, with dietary supplements growing at a mid to high single-digit rate.
biote Corp. amended and restated the employment agreement for Robert Peterson in connection with his role as Interim Chief Executive Officer. Under the new terms, he will receive an annual base salary of $658,800 plus eligibility for an annual incentive of up to 72.5% of base salary.
Peterson will be granted stock options to purchase a number of shares equal to 0.56% of biote’s outstanding common stock as of June 8, 2026, with an additional option grant for the same percentage if he becomes non-interim CEO. The agreement provides 12 months of salary and health insurance benefits if he is terminated without cause or resigns for specified good reasons, with enhanced payments (salary plus target bonus and accelerated vesting of certain equity awards) if such a termination occurs around a change in control.
Biote Corp. announced a leadership transition while keeping its 2026 outlook intact. Bret Christensen will step down as Chief Executive Officer of BioTE effective June 8, 2026, but will remain on the Board as a Class III director and receive a new stock option for 130,000 shares as part of a separation agreement. Robert Peterson, currently Chief Financial Officer and Chief Business Officer, will become Interim Chief Executive Officer and join the Board as a Class I director, continuing to serve as principal financial officer. The Board also appointed Marc Beer as Executive Chairman, with annual base compensation of $521,200, an annual bonus opportunity of up to 85% of base pay, and an option to purchase 114,157 shares.
Under Mr. Beer’s services agreement, if his role ends without cause or he resigns for specified good reason around a change in control, he is entitled to 18 months of salary and target bonus continuation, COBRA premium payments for up to 18 months, and full vesting of certain equity awards. In its accompanying press release, Biote reaffirmed full-year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of 2026, signaling that management expects to pursue existing growth and profitability plans despite the CEO transition.
biote Corp. reported the results of its 2026 annual meeting of stockholders. Stockholders elected two Class I directors, Andrew R. Heyer and Dana Jacoby, to serve until the 2029 annual meeting and until their successors are elected and qualified or earlier departure.
Heyer received 22,759,692 votes for and 3,960,800 withheld, while Jacoby received 23,020,635 votes for and 3,699,857 withheld. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 29,507,419 votes for, 67,387 against, and 7,390 abstentions.
Biote Corp. reported first quarter 2026 revenue of $44.9 million, down 8.3% from $49.0 million, as procedure volumes were hurt by a voluntary recall of certain hormone pellet products. Gross margin slipped to 68.9% from 74.3%, and operating income fell to $3.2 million from $9.7 million.
Net income declined to $2.7 million (diluted EPS $0.06) from $15.8 million ($0.37), largely because the gain from changes in earnout liabilities dropped to $2.1 million from $10.7 million. Adjusted EBITDA was $8.7 million, a 36.6% decrease, with margin down to 19.4% from 28.1%.
Dietary supplements revenue grew 19.1% to $11.0 million, partly offsetting a 13.2% decline in procedure revenue to $31.3 million. Management reaffirmed 2026 guidance for revenue above $190 million and Adjusted EBITDA above $38 million, and continues to expect procedure revenue to return to growth in the second half of 2026.
biote Corp. filed a report to share an updated investor presentation that outlines its 2025 performance and 2026 outlook. For 2025, the company reports revenue of $192.2 million and Adjusted EBITDA of $53.5 million, reflecting a 27.8% Adjusted EBITDA margin. The presentation also provides 2026 guidance, targeting revenue above $190 million and Adjusted EBITDA above $38 million, and describes Biote’s strategy to expand its hormone optimization and broader therapeutic wellness offerings through a scalable practitioner network and proprietary technology platform.
Biote Corp. reported 2025 revenue of $192.2 million, down 2.5% from 2024, as procedure revenue declined 8.8% while dietary supplements grew 19.1%. Gross margin improved to 71.5%, and operating income rose 12.5% to $35.6 million helped by lower operating expenses from a sales reorganization.
Net income jumped to $31.6 million (diluted EPS $0.74) from $0.05 million (EPS $0.09), largely influenced by a $13.0 million gain from changes in earnout liabilities. Adjusted EBITDA declined 8.1% to $53.5 million, with margin slipping to 27.8%. For 2026, Biote guides revenue to above $190 million and Adjusted EBITDA above $38 million, reflecting a planned step-up in sales and technology investments, with procedure revenue expected to fall in the first half before returning to growth in the second half.
biote Corp. reported that its wholly owned subsidiary, F.H. Investments, Inc. (Asteria Health), has initiated a voluntary recall of certain hormone pellet lots shipped between May 20, 2025 and January 19, 2026 because of a potential presence of metal particulate matter. The recall is being carried out with the knowledge of the U.S. Food and Drug Administration.
The company expects to record a one-time charge of approximately $1.3 million to fourth quarter cost of products for the write-off of affected pellet inventory and currently estimates additional recall-related costs of about $1.0 million in 2026. biote does not believe its fourth quarter business was affected beyond the inventory write-off and does not anticipate a material impact on its ability to supply pellets to practitioner partners or on practitioners’ ability to serve patients.
biote Corp. (BTMD) reported that it issued a press release covering financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to an Item 2.02 Form 8-K.
The company notes the information is being furnished, not filed, which means it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated.